A detailed history of Td Asset Management Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 33,480 shares of KRYS stock, worth $5.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
33,480
Previous 58,080 42.36%
Holding current value
$5.18 Million
Previous $10.7 Million 42.92%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$174.7 - $213.66 $4.3 Million - $5.26 Million
-24,600 Reduced 42.36%
33,480 $6.09 Million
Q2 2024

Aug 02, 2024

SELL
$153.12 - $183.64 $1.7 Million - $2.04 Million
-11,082 Reduced 16.02%
58,080 $10.7 Million
Q1 2024

May 08, 2024

BUY
$108.01 - $179.35 $3.05 Million - $5.06 Million
28,200 Added 68.84%
69,162 $12.3 Million
Q4 2023

Feb 12, 2024

BUY
$96.0 - $128.29 $1.78 Million - $2.38 Million
18,542 Added 82.7%
40,962 $5.08 Million
Q3 2023

Oct 27, 2023

BUY
$108.51 - $130.22 $717,251 - $860,754
6,610 Added 41.81%
22,420 $2.6 Million
Q2 2023

Aug 09, 2023

BUY
$78.48 - $130.32 $1.24 Million - $2.06 Million
15,810 New
15,810 $1.86 Million
Q4 2020

Feb 16, 2021

SELL
$40.64 - $61.38 $647,070 - $977,292
-15,922 Closed
0 $0
Q3 2020

Nov 10, 2020

SELL
$37.76 - $48.49 $333,534 - $428,312
-8,833 Reduced 35.68%
15,922 $685,000
Q2 2020

Aug 13, 2020

BUY
$37.03 - $60.0 $148,120 - $240,000
4,000 Added 19.27%
24,755 $1.03 Million
Q1 2020

May 15, 2020

SELL
$35.02 - $65.64 $185,606 - $347,892
-5,300 Reduced 20.34%
20,755 $897,000
Q4 2019

Feb 11, 2020

BUY
$33.17 - $65.23 $19,902 - $39,138
600 Added 2.36%
26,055 $1.44 Million
Q3 2019

Nov 07, 2019

BUY
$34.72 - $51.3 $187,488 - $277,020
5,400 Added 26.93%
25,455 $884,000
Q2 2019

Aug 01, 2019

BUY
$27.2 - $41.2 $323,734 - $490,362
11,902 Added 145.98%
20,055 $808,000
Q1 2019

May 08, 2019

BUY
$19.86 - $32.9 $161,918 - $268,233
8,153 New
8,153 $268,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.97B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.